The Zhitong Finance App learned that before the US stock market on Tuesday, Pfizer (PFE.US) announced financial results for the second quarter of 2026. Against the backdrop of continued decline in revenue from COVID-19 products, the company achieved higher than expected revenue growth with the strong performance of non-COVID-19 core products such as Eliquis and Padcev, and raised the lower limit of the annual revenue guidance. However, the impairment of non-cash intangible assets of $4.3 billion dragged GAAP to record a net loss, and the stock price rose slightly by about 0.52% to $25.16 in pre-market trading.

Zhitongcaijing · 1d ago
The Zhitong Finance App learned that before the US stock market on Tuesday, Pfizer (PFE.US) announced financial results for the second quarter of 2026. Against the backdrop of continued decline in revenue from COVID-19 products, the company achieved higher than expected revenue growth with the strong performance of non-COVID-19 core products such as Eliquis and Padcev, and raised the lower limit of the annual revenue guidance. However, the impairment of non-cash intangible assets of $4.3 billion dragged GAAP to record a net loss, and the stock price rose slightly by about 0.52% to $25.16 in pre-market trading.